Mixed-phenotype acute leukemia treated with decitabine

Korean J Intern Med. 2016 Mar;31(2):406-8. doi: 10.3904/kjim.2014.353. Epub 2016 Feb 15.

Authors

Ji-Young Lee¹, Sang-Min Lee¹, Ja-Young Lee², Ki-Hyang Kim¹, Moon-Young Choi¹, Won-Sik Lee¹

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
² Department of Laboratory Medicine, Inje University Busan Paik Hospital, Busan, Korea.

No abstract available

Keywords: Decitabine; Mixed-phenotype acute leukemia.

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / analogs & derivatives*
Azacitidine / therapeutic use
Biomarkers, Tumor / analysis
Biomarkers, Tumor / genetics
Biopsy
Bone Marrow Examination
Cell Lineage
Decitabine
Female
Humans
Leukemia, Biphenotypic, Acute / drug therapy*
Leukemia, Biphenotypic, Acute / genetics
Leukemia, Biphenotypic, Acute / pathology
Phenotype
Remission Induction
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Biomarkers, Tumor
Decitabine
Azacitidine